Lennox International Inc. (LII: Quote), engaged in heating, air conditioning, and refrigeration businesses, raised FY12 EPS and revenue guidance above estimates.
- Raises FY12 adjusted EPS expectations from ongoing operations to $2.60-2.80 from $2.35-2.65. Consensus $2.51.
- Raises FY12 GAAP EPS from continuing operations guidance to a range of $2.55-$2.75 from $2.30-$2.60.
- Raises FY12 revenue growth expectations to a range of 5-7% from 3-6% at constant currency. Assuming a negative 1 point impact from foreign exchange on a full-year basis, the company sees revenue growth of 4-6% at actual currency. Consensus negative growth of 0.5%.
Supernus Pharmaceuticals Inc. (SUPN: Quote) said its experimental epilepsy drug Oxtellar XR won FDA approval. This is the second drug approval for the company since its May IPO. In June, the company won tentative approval on Trokendi XR, another epilepsy treatment. Oxtellar is slated for launch in the first quarter of 2013.
Click here to receive FREE breaking news email alerts for Lennox International Inc and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org